Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

The purpose of this study was to estimate in all randomised trials the relative risk of overall response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS), and toxicity of aromatase inhibitors (AI), compared with tamoxifen (Tam) as first-line endocrine therapy in po...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ferretti, G, Bria, E, Giannarelli, D, Felici, A, Papaldo, P, Fabi, A, Di Cosimo, S, Ruggeri, E M, Milella, M, Ciccarese, M, Cecere, F L, Gelibter, A, Nuzzo, C, Cognetti, F, Terzoli, E, Carlini, P
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2006
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361349/
https://ncbi.nlm.nih.gov/pubmed/16736002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603194
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi